Therapeutic Response

EGFR activating variants status confers therapeutic sensitivity to Afatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Giotrif (afatinib) [product monograph]. HC. Health Canada approved afatinib for the treatment of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s).